

**HHCS Human Hepatocytes Cryopreserved for Suspension assays
Cell Specification – Certificate of Analysis (CoA)**

Lot HH240620

Batch Release: August 12, 2024

Donor data

Species: Human

Gender: male

Age: 82 years

Diagnosis: HCC (Hepatocellular carcinoma)
Medical History: Hypertension

Therapy: Hemihepatectomy right
Medication: Amlodipin, Torasemid, Pentoprazol,
Clopidogrel, Allopurinol
Serology: HAV, HBV, HCV, HIV 1/2: negative

Cryopreservation and Thawing

Cryopreservation:

Date: June 20, 2024

Amount per vial: 10.0 x 10⁶ cells

Thawing: n=1

Post-thaw viability: 91.8 %

Post-thaw yield per vial: 4.9 x 10⁶ cells

Recovery: 48.9 %

Suspension culture

Viability test on orbital shaker (Eppendorf Thermomixer C, 1000 rpm at 37 °C with 0.5 x 10⁶ cells in 0.5 ml HPM-Cryo):

Time (h)	0	1	2	3	4	5
Viability (%)	91.8	72.5	72.5	69.9	64.3	63.0

Note: Yield, viability, recovery and activity assays were performed at PRIMACYT using PRIMACYT's manual for thawing, plating and culture of primary cryopreserved hepatocytes.

Store at -150 °C or in the vapour phase of LN₂

This product should be considered as potential biohazard. Only intended for *in vitro* use.

Issued by: M. Reu

Verified by: K. Damrau